Antiviral associated with 26% reduced risk for long COVID

The antiviral nirmatrelvir, which is part of Paxlovid, was linked to a significant reduction in the risk for long COVID and post-acute death in patients with at least one risk factor for severe illness, according to researchers.Recent research has indicated that nearly 19 million adults in the United States may have long COVID. The condition has had a substantial impact on patients, many of whom

Related Keywords

New York ,United States ,Vasiliki Tsampasian ,Mitchellh Katz ,Ryan Xie ,Clinical Epidemiology Center ,Health Education England ,York City Health ,United States Department ,Louis Veterans Affairs Va Health Care System ,Louis Veterans Affairs ,Health Care System ,New York City Health ,